ผลบอลวันนี้_ตู้ปลาคาสิโน_คาสิโน ออนไลน์ ฟรีเครดิต
An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.?
Pictured right: Lawson scientist, Dr. Alison Allan?
The study used a liquid biopsy test developed by molecular diagnostics company Epic Sciences that examines circulating tumour cells (CTCs) in blood samples from patients with advanced prostate cancer who are deciding whether to switch from hormone-targeting therapy to chemotherapy.?CTCs are cancer cells that leave a tumour, enter the blood stream and invade other parts of the body, causing the spread of cancer.
The test identifies whether or not a patient’s?CTCs contain a protein called?AR-V7?in the cell’s nucleus. The research team set out to determine whether the presence of this protein predicted which treatment would best prolong a patient’s life. They found that patients who tested positive for the protein responded best to taxane-based chemotherapy while those who tested negative for the protein responded best to hormone-targeting therapy with drugs called androgen-receptor signaling (ARS) inhibitors. These are the two most widely used drug classes to treat advanced prostate cancer.
Research participants included 142 patients with advanced prostate cancer from the London Regional Cancer Program at London Health Sciences Centre (LHSC) in London, Ontario; Memorial Sloan Kettering Cancer Center in New York; and the Royal Marsden in London, England. The patients had already undergone at least one round of hormone-targeting therapy without success and were working with their oncologist to decide whether to switch to a different hormone-targeting therapy or to chemotherapy as their next line of treatment. The study was blinded; patients and their oncologists did not know whether or not the patient’s?CTCs were positive for?AR-V7. The choice of therapy was at the discretion of the physician.??
Hormone-targeting therapies like?ARS?inhibitors work by slowing or stopping the growth of cancers that use hormones to grow. Prostate cancer growth relies on hormones called androgens, which include testosterone. Androgen deprivation therapy like?ARS?inhibitors blocks the production of male hormones to treat the recurrence or spread of prostate cancer.
“ARS?inhibitors are the preferred first line of treatment because they target the hormones that provide the fuel for prostate cancer cells to grow,” explains Dr. Allan. “However, at some point, cancer cells can figure out a way to survive without this fuel and become resistant to?ARS?inhibitors, in many cases through production of the?AR-V7?protein. That’s why chemotherapy is sometimes used a second line therapy.”
While this study looked at predicting the best treatment for patients who had already undergone at least one round of hormone-targeting therapy, a future goal of the team is to assess the use of this test or similar?CTC?blood tests in determining optimal therapy at earlier decision points in advanced prostate cancer care. The team also plans to collaborate further with Epic Sciences to evaluate different versions of the?CTC?blood test for other types of cancer, such as lung cancer.
Story courtesy of Lawson Health Research Institute?